Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3447-3452

  Horne, K C ^a   Howden, B P ^a,b,c   Grabsch, E A ^b   Graham, M ^a   Ward, P B ^b   Xie, S ^b   Mayall, B C ^b   Johnson, P D R ^a,d   Grayson, M L ^a,b,c,d  

^a AUSTIN HOSPITAL   (Australia)

^b AUSTIN HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; LINEZOLID; METICILLIN; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BROTH DILUTION; CONTROLLED STUDY; HETEROZYGOSITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STRAIN DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 67749139788     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01365-08     Document Type: Article

References (22)

1. American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
2. Ballard, S. A., K. K. Pertile, M. Lim, P. D. Johnson, and M. L. Grayson. 2005. Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob. Agents Chemother. 49:1688-1694.
3. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
4. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Coombs, G. W., G. R. Nimmo, J. M. Bell, F. Huygens, F. G. O'Brien, M. J. Malkowski, J. C. Pearson, A. J. Stephens, P. M. Giffard, and the Australian Group for Antimicrobial Resistance. 2004. Genetic diversity among community methicillin-resistant Staphylococcus aureus strains causing outpatient infections in Australia. J. Clin. Microbiol. 42:4735-4743.
6. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
7. Donner, A. 1984. Approaches to sample size estimation in the design of clinical trials-a review. Stat. Med. 3:199-214.
8. Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
9. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, and F. C. Tenover. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439.
10. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448-454.
11. Goering, R. 2004. Pulsed-field gel electrophoresis, p. 185-196. In D. Persing, F. Tenover, J. Versalovic, Y. Tang, and E. Unger (ed.), Molecular microbiology diagnostic principles and practice. ASM Press, Washington, DC.
12. Grayson, M. L., G. W. Gibbons, G. M. Habershaw, D. V. Freeman, F. B. Pomposelli, B. I. Rosenblum, E. Levin, and A. W. Karchmer. 1994. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limbthreatening foot infections in diabetic patients. Clin. Infect. Dis. 18:683-693.
13. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
14. Horan, T., and R. Gaynes. 2004. Surveillance of nosocomial infections, p. 1659-1702. In G. Mayall (ed.), Hospital epidemiology and infection control. Lippincott Williams and Wilkins, Philadelphia, PA.
15. Horne, K. C., M. Graham, P. B. Ward, B. P. Howden, S. Xie, P. D. R. Johnson, B. Mayall, and M. L. Grayson. 2006. Vancomycin-intermediate Staphylococcus aureus (hVISA/VISA) and vancomycin-susceptible methicillin-resistant S. aureus (VSSA) have similar rates of clinical disease and overall outcomes when assessed prospectively, abstr. K-785, p. 326. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
16. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
17. Howden, B. P., P. B. Ward, S. Xie, J. Wang, P. D. R. Johnson, P. G. P. Charles, and M. L. Grayson. 2004. Identification of a new agar dilution screening method for the accurate detection of heterogenous-vancomycin intermediate Staphylococcus aureus (hVISA), abstr. D-59, p. 140. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC.
18. Lina, G., Y. Piémont, F. Godail-Gamot, M. Bes, M. O. Peter, V. Gauduchon, F. Vandenesch, and J. Etienne. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132.
19. Murchan, S., M. E. Kaufmann, A. Deplano, R. de Ryck, M. Struelens, C. E. Zinn, V. Fussing, S. Salmenlinna, J. Vuopio-Varkila, N. El Solh, C. Cuny, W. Witte, P. T. Tassios, N. Legakis, W. van Leeuwen, A. van Belkum, A. Vindel, I. Laconcha, J. Garaizar, S. Haeggman, B. Olsson-Liljequist, U. Ransjo, G. Coombes, and B. Cookson. 2003. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J. Clin. Microbiol. 41:1574-1585.
20. Stevens, D. L. 2006. The role of vancomycin in the treatment paradigm. Clin. Infect. Dis. 42(Suppl. 1):S51-S57.
21. Walsh, T. R., A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
22. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.